Research Publications

In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.

Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE

Prognostic value of myeloperoxidase in patients with chest pain.

Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL

Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.

Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, Topol EJ

Current status and future prospects for acute myocardial infarction therapy.

Topol EJ

Anticoagulation with prosthetic cardiac valves.

Topol EJ, APPCR Consensus Panel

Pharmaceutical advertising versus research spending: are profits more important than patients?

Mukherjee D, Topol EJ

A matter of life and death? The Heart Protection Study and protection of clinical trial participants.

Migrino RQ, Topol EJ, Heart Protection Study

Preprocedural white blood cell count and death after percutaneous coronary intervention.

Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ, TARGET Investigators

Identification of new genes differentially expressed in coronary artery disease by expression profiling.

Archacki SR, Angheloiu G, Tian XL, Tan FL, DiPaola N, Shen GQ, Moravec C, Ellis S, Topol EJ, Wang Q